A 14-Year-Old with Recurrent Rhabdomyolysis: Interpreting a Nondiagnostic Acylcarnitine Profile
A 14-year-old girl presents with her third episode of severe muscle pain and dark urine, each triggered by prolonged exercise or fasting during illness. During the current episode: CK 28,000 U/L, urine dipstick positive for blood but microscopy shows no red cells, serum creatinine 0.9 mg/dL, glucose 4.0 mmol/L, lactate 1.9 mmol/L, ammonia normal, liver enzymes mildly elevated. Between episodes she is entirely well with normal exam and normal CK. Plasma acylcarnitine profile during the acute episode is reported as 'nondiagnostic; no diagnostic abnormality detected.' Urine organic acids show nonspecific dicarboxylic acids. Acylcarnitine was drawn 6 hours after presentation and after IV fluids with dextrose were started. Free carnitine is low-normal. The family asks whether 'the muscle enzyme test' can be done to confirm the diagnosis.
1. Why might the acylcarnitine profile be falsely reassuring here, and what sampling/analytic issues would you address before concluding the test is normal?
Read the worked answer
Several confounders can mask a fatty acid oxidation defect:
- Timing relative to treatment: acylcarnitines can normalize rapidly once dextrose is given and catabolism is reversed. The sample was drawn 6 hours in, after IV dextrose - a key confounder. The most informative sample is during active catabolism/crisis, before treatment, or after a controlled fasting/provocative protocol in a monitored setting.
- Specimen type: plasma vs. dried blood spot vs. urine can differ; some species are better captured in one matrix. Confirm the lab used a validated panel that includes the relevant long-chain species and that internal standards were acceptable.
- Low free carnitine: if total carnitine is low, the acylcarnitine species may be present at low absolute concentrations; a 'nondiagnostic' report can reflect low substrate rather than normal metabolism.
- Mild/attenuated forms: some defects (e.g., mild VLCAD, CPT2, or partial defects) show only subtle or intermittent abnormalities.
- Analytic sensitivity/interpretation: ask whether the lab flagged any species as borderline and whether the reporting cutoffs are age-appropriate.
Do not accept 'nondiagnostic' as 'normal' without knowing the timing, matrix, and whether free carnitine was low enough to blunt the profile. Repeat sampling during a controlled fast or early in a crisis, before dextrose, is the highest-yield next step.
2. The family requests 'the muscle enzyme test.' How do you weigh muscle biopsy with enzymatic testing against molecular and other approaches, and what is your diagnostic strategy?
Read the worked answer
Weighing options:
- Muscle biopsy with enzyme assay (e.g., fatty acid oxidation enzymes, respiratory chain): historically useful, but invasive, subject to sampling and pre-analytic degradation (enzymes are labile; transport on ice and rapid processing matter), and increasingly superseded by molecular testing. Reserve it for cases where molecular testing is uninformative and the clinical suspicion remains high, or where a tissue-specific defect is suspected.
- Molecular testing: a multigene panel or exome covering fatty acid oxidation (CPT2, VLCAD/ACADVL, LCHAD/HADHA, trifunctional protein, etc.) and glycogen/other muscle energy disorders is the preferred next step - noninvasive, and can detect mild/attenuated variants that biochemical testing misses. Include deletion/duplication analysis.
- Targeted biochemical provocation: a supervised fasting study or exercise test with serial acylcarnitines, organic acids, and CK can unmask intermittent defects, but only in a monitored setting with safety precautions.
- Urine organic acids showing dicarboxylic acids during crisis support a fatty acid oxidation defect but are nonspecific.
Strategy: (1) repeat acylcarnitine early in a crisis before dextrose, plus acylglycines and free/total carnitine; (2) send a comprehensive molecular panel; (3) if both are unreconciled and suspicion is high, discuss muscle biopsy with enzymatic testing as a complementary, not first-line, test. Counsel the family that a normal single test does not exclude the diagnosis and that the goal is to prevent rhabdomyolysis and renal injury.
3. Regardless of the eventual diagnosis, what management and safety counseling applies now, and what monitoring do you recommend?
Read the worked answer
Acute and preventive management for recurrent rhabdomyolysis of suspected metabolic origin:
- Avoid triggers: prolonged fasting and prolonged vigorous exercise; during intercurrent illness, maintain carbohydrate intake and seek early care. Provide a written 'sick-day' plan.
- Acute crisis: aggressive IV hydration to protect the kidneys; monitor CK, electrolytes (watch for hyperkalemia, hypocalcemia, hyperphosphatemia), and renal function; treat hyperkalemia; consider urine alkalinization per protocol. Avoid nephrotoxins.
- Diet: ensure adequate carbohydrate; some fatty acid oxidation defects benefit from medium-chain triglyceride (MCT) supplementation and a low long-chain fat diet, but this is diagnosis-specific - do not start empirically without a diagnosis. A metabolic dietitian should be involved.
- Avoid fasting and certain medications (e.g., valproate) and review anesthetic risk if a fatty acid oxidation defect is confirmed.
- Monitoring: baseline and interval CK, renal function, and growth/nutrition; educate school and family about early signs (muscle pain, dark urine).
- Counseling: explain that the diagnosis is not yet established, that a normal test does not rule it out, and that the plan is to catch the next episode early with pre-treatment sampling. Document the plan and give the family a copy.